Physician profile
Maria Polizzi
NPI 1679543953
$1,558.95
in general payments reported to CMS, 2019-2025
21 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $414 · 2021: $210 · 2022: $290 · 2023: $178 · 2024: $162 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $271.05 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $222.03 | 2022-2025 | |
| Novo Nordisk INC | $178.38 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $148.93 | 2020-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $105.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $98.11 | 2019-2020 | |
| Abbvie INC. | $82.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.54 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $75.07 | 2020-2023 | Fasenra |
| Topcon Healthcare Solutions, INC. | $68.58 | 2020-2021 | |
| Pfizer INC. | $48.01 | 2021-2024 | |
| Esperion Therapeutics, INC. | $28.39 | 2021 | |
| Quidel Corporation | $25.95 | 2019 | |
| Astellas Pharma US INC | $18.85 | 2023 | Veozah |
| Indivior INC. | $17.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $17.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.37 | 2020 | |
| Genentech USA, INC. | $14.15 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Polizzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.